Welcome to our dedicated page for EDGEWELL PERSONAL CARE Co SEC filings (Ticker: EPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EDGEWELL PERSONAL CARE Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EDGEWELL PERSONAL CARE Co's regulatory disclosures and financial reporting.
Edgewell Personal Care Co reports an institutional Schedule 13G filing showing Vanguard Portfolio Management beneficially owned 6.56% of Common Stock, equal to 3,065,063 shares as of 03/31/2026.
Vanguard Portfolio Management disclosed sole dispositive power over 3,065,063 shares and sole voting power for 136,694 shares. The filing is signed by Ashley Grim on 04/29/2026.
Edgewell Personal Care Co: an amendment to a Schedule 13G/A from The Vanguard Group reports zero beneficial ownership of Edgewell common stock following an internal realignment. The filing states that, effective January 12, 2026, certain Vanguard subsidiaries and business divisions will report holdings separately and that The Vanguard Group, Inc. no longer is deemed to beneficially own securities held by those affiliates. The filing is signed on 03/26/2026 and lists 0 shares and 0% ownership for The Vanguard Group in Edgewell common stock.
Brandes Investment Partners, L.P. reports beneficial ownership of 6,121,589 common shares of Edgewell Personal Care Co., representing 13.1% of the class as of the reported date.
Brandes has shared voting power over 4,112,649 shares and shared dispositive power over all 6,121,589 shares, with no sole voting or dispositive authority. The firm files as an investment adviser and certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of Edgewell.
Edgewell Personal Care reported first‑quarter fiscal 2026 net sales of $422.8 million, up 1.9% year over year, but swung to a much larger loss. From continuing operations, the company posted a net loss of $29.2 million, with total net loss of $65.7 million including discontinued operations.
Results were hit by $18.1 million of restructuring charges and $5.8 million of related costs, plus a $37.4 million goodwill impairment and $3.8 million loss on assets held for sale tied to the divestiture of the Feminine Care segment. Gross profit fell to $161.0 million and gross margin declined as inflation, tariffs and lower volume outweighed productivity savings.
Wet Shave sales slipped to $291.3 million and segment profit declined to $42.2 million, while Sun and Skin Care sales rose 9.0% to $131.5 million but remained slightly unprofitable. Operating cash flow was negative $125.9 million, and total borrowings reached $1.56 billion, including $277.0 million drawn on the U.S. revolver. The sale of Feminine Care to Essity for about $340 million closed after quarter‑end and is earmarked primarily for debt reduction and reinvestment.
Edgewell Personal Care Co. director Sit Swan reported an equity grant. On February 5, 2026, the director was awarded 7,817 restricted stock equivalents at a price of $0 per unit, held directly.
These restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual shareholder meeting, unless the director elects to defer conversion until service on the Board ends.
Edgewell Personal Care Company director Rakesh Sachdev reported an equity award in the form of derivative securities. On February 5, 2026, he received 7,817 restricted stock equivalents at a price of $0 per unit, all held as a direct ownership position.
According to the filing, these restricted stock equivalents are designed to convert into the same number of shares of Edgewell common stock on the day preceding the next annual meeting of shareholders, unless Sachdev elects to defer conversion until his service on the Board of Directors ends. After this transaction, he beneficially owns 7,817 derivative securities tied to Edgewell common stock.
Edgewell Personal Care director Stephanie Stahl reported a new equity grant. On February 5, 2026, she acquired 7,817 restricted stock equivalents at a price of $0 per unit. These are derivative securities that track the value of Edgewell common stock.
The restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual meeting of shareholders, unless Stahl elects to defer conversion until her service on Edgewell’s Board of Directors ends. After this grant, she beneficially owned 7,817 derivative units directly.
Edgewell Personal Care Company director receives equity grant. Director John C. Hunter III was granted 7,817 restricted stock equivalents of Edgewell common stock at a price of $0 on 02/05/2026. These restricted stock equivalents convert into common shares on the day before the next annual shareholder meeting, unless he elects to defer conversion until his service on the Board ends.
Edgewell Personal Care Company director Corbin George reported receiving 7,817 restricted stock equivalents on February 5, 2026. These derivative securities were acquired at a price of $0 and are held as direct ownership.
According to the filing, the restricted stock equivalents convert into shares of Edgewell common stock on the day before the next annual meeting of shareholders, unless the director elects to defer conversion until service on the Board ends.
Edgewell Personal Care Company director equity grant
Edgewell Personal Care Company reported that director Gary Waring received an award of 7,817 restricted stock equivalents on February 5, 2026. These derivative securities were granted at a price of $0 per unit and are held in his direct ownership.
The restricted stock equivalents convert into shares of Edgewell common stock on the day preceding the next annual meeting of shareholders, unless Waring elects to defer conversion until his service on Edgewell’s Board of Directors ends. After this grant, he beneficially owns 7,817 restricted stock equivalents.